Rep. Eshoo Applauds New FDA Draft Guidance for Diversity in Clinical Trials
June 26, 2024
June 26, 2024
WASHINGTON, June 26 -- Rep. Anna G. Eshoo, D-California, issued the following news release:
Health Subcommittee Ranking Member Anna G. Eshoo (CA-16) made the following statement in response to the Food and Drug Administration's (FDA) draft guidance to boost diversity in clinical trials:
"Two years ago, my Diverse and Equitable Participation in Clinical Trials (DEPICT) Act was signed into law, creating the first-ever requirement in law for drug and device companies . . .
Health Subcommittee Ranking Member Anna G. Eshoo (CA-16) made the following statement in response to the Food and Drug Administration's (FDA) draft guidance to boost diversity in clinical trials:
"Two years ago, my Diverse and Equitable Participation in Clinical Trials (DEPICT) Act was signed into law, creating the first-ever requirement in law for drug and device companies . . .